Metraipolis › archive › dc_9ccc6832bb12
Concurrent naxitamab and lorlatinib in a patient with refractory high-risk neuroblastoma: a case report — Europe PMC PMID:41948498
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41948498
- DOI
- 10.3389/fonc.2026.1790294
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-04T02:43:15.191Z
- SHA-256 of the archived text
19d8e787ccc99a44787ca545cbcafe274b9effaf11e3ee1223ea5c2da8b4cb7b- Stable URL of this page
https://metraipolis.com/documento/dc_9ccc6832bb12
How to cite
Concurrent naxitamab and lorlatinib in a patient with refractory high-risk neuroblastoma: a case report — Europe PMC PMID:41948498 — Europe PMC (en), https://europepmc.org/article/MED/41948498 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_9ccc6832bb12 (Metraipolis archive dc_9ccc6832bb12, sha256 19d8e787ccc99a44787ca545cbcafe274b9effaf11e3ee1223ea5c2da8b4cb7b)
BibTeX
@misc{dc9ccc6832bb12,
title = {Concurrent naxitamab and lorlatinib in a patient with refractory high-risk neuroblastoma: a case report — Europe PMC PMID:41948498},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41948498},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_9ccc6832bb12; sha256 19d8e787ccc99a44787ca545cbcafe274b9effaf11e3ee1223ea5c2da8b4cb7b},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41948498. Agents can read the archived copy with the MCP tool read_document.